BTOG 2020 | New agents for EGFR+ NSCLC: osimertinib and beyond

Natasha Leighl, BSc, MMSc, MD, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Canada, discusses the emergence of the new EGFR inhibitor osimertinib following the FLAURA trial, highlighting the benefits and challenges of this. She explains the incidence of resistance and the potential mechanisms of this, such as EGFR C797S mutation. Next, she discusses exciting new trials and novel approaches in this group. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress, held in Dublin, UK.